- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00767299
A Study of Arzoxifene to Treat Korean Women With Osteoporosis
Effects of Arzoxifene on Bone Mineral Density in Korean Postmenopausal Women With Osteoporosis
The study is for Korean women who are postmenopausal and also suffer from osteoporosis.
The study will test if women who are given 20 mg of arzoxifene once a day for six months have a less severe level of osteoporosis than those women who do not take arzoxifene.
All patients will receive 500 mg of elemental calcium and 400 to 600 IU Vitamin D daily starting 4 weeks prior to study drug administration continuing through the 6 months of therapy.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bucheon, Korea, Republic of, 420-767
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Seoul, Korea, Republic of, 138-736
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Present with osteoporosis based on total hip, femoral neck or lumbar spine BMD T-score of less than or equal to -2.5 but must never have had any osteoporotic fragility fracture.
- Are ambulatory and are 60 to 85 years of age, inclusive. Aside from diagnosed osteoporosis (Inclusion Criterion [1]), all women must be free of severe or chronically disabling conditions, have a life expectancy of at least 5 years in the opinion of the investigator, be expected to remain ambulatory throughout the entire study, and be expected to return for follow-up visits.
- Had their last natural menstrual period at least 2 years before beginning the study.
- Are able to comprehend the requirements and procedures for the study and to provide informed consent before entering the study.
- Have at least two lumbar vertebrae (L1 to L4) that are evaluable via dual energy X-ray absorptiometry (DXA) and lateral thoracic and lumbar spine x-ray films that can be adequately evaluated for existing vertebral fractures at screening.
- Have centrally read total hip, femoral neck or lumbar spine T-score less than or equal to -2.5
Exclusion Criteria:
- Have known current metabolic bone disorders other than low bone mass, such as hyperparathyroidism, renal osteodystrophy, or osteomalacia.
- Have known, suspected, or history of carcinoma of the breast or estrogen-dependent neoplasia (e.g., endometrial or uterine carcinoma), except for hysterectomized patients with a history of carcinoma in situ of the uterus. For other cancers, be disease free and in remission from all other cancers for 5 or more years, except for excised superficial lesions, such as basal cell carcinoma or squamous cell carcinoma of the skin.
- Have demonstrated or suspected allergy to raloxifene or arzoxifene
- Have unexplained or abnormal vaginal bleeding within 6 months prior to Visit 1 or between Visit 1 and Visit 2.
- Are experiencing clinically severe postmenopausal symptoms that may require estrogen-replacement therapy.
- Have a history of or suggestion on ultrasound or pelvic examination of a pre-existing gynecologic abnormality that would require further gynecologic treatment (e.g., ovarian cysts, large fibroids, undiagnosed adnexal masses) or of baseline endometrial thickness of >5 mm.
- Have Papanicolaou's tests showing malignant or premalignant findings.
- Have active or any past history of thromboembolic events
- Have active or any past history of atrial fibrillation.
- Have a history of cerebrovascular accident or documented transient ischemic attack at any time in the past.
- Have acute or chronic liver disease defined as alanine aminotransaminase (ALT) >100 U/L, gamma-glutamyl transferase (GGT) >400 U/L, or late stage cirrhosis without transaminase elevations.
- Have impaired kidney function (serum creatinine >177 micromol/L or >2.0 mg/dL).
- Have vitamin D deficiency prior to enrollment (Visit 2; 25-hydroxyvitamin D less than10 ng/mL or less than 24.9 nmol/L).
- Have any known, severe, or untreated malabsorption syndromes.
- Have endocrine disorders requiring pharmacologic therapy except for type II diabetes and hypothyroidism. Patients on a stable dose of thyroid replacement therapy during the 6 months preceding randomization (Visit 2) who are clinically euthyroid in the opinion of the investigator may enroll in the trial.
- Consume an excess of alcohol or abuse drugs
- Represent an unacceptable medical or psychiatric risk for treatment with an investigational drug
- Have active or any history of seizure disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
20 mg, QD, PO,24 weeks
Other Names:
|
Placebo Comparator: 2
|
QD, PO, 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Lumbar spine bone mineral density (BMD), by dual energy X-ray absorptiometry (DXA) analyses
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of spontaneous vaginal bleeding.
Time Frame: 6 months
|
6 months
|
Total hip BMD
Time Frame: 6 months
|
6 months
|
Biochemical marker of bone metabolism (serum CTX and PINP)
Time Frame: 3 and to 6 months
|
3 and to 6 months
|
Overall safety of arzoxifene administration in Korean postmenopausal women
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12185
- H4Z-MC-GJAV
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
Clinical Trials on arzoxifene
-
Eli Lilly and CompanyCompletedBreast Cancer | Ovarian Cancer | Endometrial CancerUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedOsteoporosis, PostmenopausalUnited States
-
Eli Lilly and CompanyCompletedOvarian Cancer | Primary Peritoneal Cavity CancerUnited States
-
Eli Lilly and CompanyCompletedEndometrial CancerUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Completed
-
University of Kansas Medical CenterNational Cancer Institute (NCI)Completed
-
Eli Lilly and CompanyCompletedOsteoporosis, PostmenopausalSpain, United States, Taiwan, Italy, Argentina, Canada, France, Australia
-
The Cleveland ClinicNational Cancer Institute (NCI)CompletedBreast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2)
-
University of Kansas Medical CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States